ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pumitamig

Also written as “Pumitamig”, “PM8002” and “BNT327”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Breast Neoplasms · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 4 companies.

Drug pagePumitamig: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 14, 202434 company-led studies, 32 open or runningCo-development: BioNTech and Bristol Myers Squibb, Jun 2025Next primary completion: Jan 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioNTech2321 open or runningphase 3since May 14, 2024Feb 15, 2023Jan 1, 2027phase 2 · NCT05879055
Bristol-Myers Squibbits history only99 open or runningphase 3since Oct 23, 2025Sep 26, 2024Mar 15, 2028phase 2 · NCT07871214
Boehringer Ingelheimits history only11 open or runningphase 2since Sep 22, 2026Sep 22, 2026Apr 17, 2030phase 2 · NCT07843940
DualityBioits history only11 open or runningphase 2since Apr 9, 2025Apr 9, 2025Jun 30, 2030phase 2 · NCT06953089
  • Named in Bristol-Myers Squibb’s own pipeline as pumitamig, phase 3, as of Oct 29, 2026 (source).

Also a collaborator on its studies: MediLink Therapeutics (Suzhou), BioNTech (Shanghai) Pharmaceuticals and Genmab.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How Boehringer Ingelheim and DualityBio relate to it is not in the registry or these sources.

History and studies of BioNTech only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Feb 15, 2023.

  1. Jun 15, 20232 phase 2 studiesNCT05918133, NCT05918107
  2. May 14, 2024Phase 3 study in Triple Negative Breast NeoplasmsNCT06419621 · 392 enrolled · China
  3. Jun 3, 20242 phase 2 studiesNCT06449222, NCT06449209
  4. Aug 21, 2024Phase 2 study in Liver NeoplasmsNCT06584071 · 140 planned
  5. Sep 23, 2024Phase 3 study in SCLCNCT06616532 · 404 enrolled · China
  6. Nov 11, 20242 phase 3 studiesNCT06712355, NCT06712316
  7. Feb 10, 20252 phase 2 studiesNCT06827236, NCT06841055
  8. Feb 13, 2025Named pumitamigINNProposed as its International Nonproprietary Name in WHO's List 132 · before, PM8002, BNT327
  9. Mar 19, 2025Phase 2 study in Small Cell Lung CarcinomaNCT06892548 · 594 planned · United States, Australia, China and more
  10. Jun 2, 2025Bristol Myers Squibb develops it with BioNTechCo-developmentWorldwide, profits and losses shared equally · announced · BioNTech
  11. Jul 3, 20252 phase 2 studiesNCT07070232, NCT07079631
  12. Aug 1, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07111520 · 880 planned · United States, Australia, China and more
  13. Sep 8, 2025Phase 3 study in Breast NeoplasmsNCT07173751 · 558 planned · United States, Argentina, Australia and more
  14. Dec 9, 2025Phase 2 study in GlioblastomaNCT07297212 · 75 planned · China
  15. Oct 14, 2026Primary completion moved from 2028-12 to 2029-04Date moved laterphase 3 · +4 months · NCT06712355
  16. Oct 22, 2026Primary completion moved from 2027-01-25 to 2027-05Date moved laterphase 3 · +4 months · NCT06616532

Ahead

  1. Jan 1, 2027Primary completion: phase 2 study in Neuroendocrine TumorsNCT05879055
  2. May 2027Primary completion: phase 3 study in SCLCNCT06616532
  3. Jun 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT06449209
  4. Jul 2027Primary completion: phase 3 study in Triple Negative Breast NeoplasmsNCT06419621

TargetBeta

“A bispecific antibody targeting both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial growth factor A (VEGF-A), with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon adm…”NCIt, read by Claude
“A bispecific antibody targeting both the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and vascular endothelial growth factor A (VEGF-A), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
HLX37Fosun Pharmaphase 32

Studies

All 23 BioNTech leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07297212Glioblastoma · China2RecruitingJan 202875
NCT07173751Breast Neoplasms · United States, Argentina, Australia and more3RecruitingDec 2029558
NCT07111520Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more2RecruitingNov 2028880
NCT07079631Colorectal Neoplasms · United States, Germany, Japan and more2RecruitingDec 2030482
NCT07070232Lethal Congenital Contracture Syndrome 2 · United States, Australia, Belgium and more2RecruitingMar 20281,438
NCT06892548Small Cell Lung Carcinoma · United States, Australia, China and more2RecruitingSep 2028594
NCT06841055Carcinoma, Non-Small-Cell Lung · United States, Australia, South Korea and more2RecruitingOct 202860
NCT06827236Breast Neoplasms · United States, Australia, Canada and more2RecruitingAug 2029380
NCT06712355Small Cell Lung Carcinoma · United States, Australia, China and more3RecruitingApr 2029621
NCT06712316Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingJan 20291,580
NCT06616532SCLC · China3Active, not recruitingMay 2027404
NCT06584071Liver Neoplasms2Not yet recruitingOct 2026140
NCT06449222Triple Negative Breast Neoplasms · United States, Australia, Turkey (Türkiye) and more2Active, not recruitingAug 202883
NCT06449209Small Cell Lung Carcinoma · United States, Australia, South Korea and more2Active, not recruitingJun 2027110
NCT06419621Triple Negative Breast Neoplasms · China3Active, not recruitingJul 2027392
NCT05918133TNBC · China2Active, not recruitingOct 30, 202642
NCT05918107MPM · China2CompletedMar 31, 202631
NCT05918445Neoplasms · China2RecruitingNov 30, 2025380
NCT05879068SCLC · China2Active, not recruitingApr 30, 202599
NCT05879055Neuroendocrine Tumors · China2Active, not recruitingJan 1, 202731
NCT05864105Carcinoma, Hepatocellular · China2CompletedJul 24, 202535
NCT05844150SCLC · China2Active, not recruitingMay 10, 202450
NCT05756972NSCLC · China2Active, not recruitingSep 13, 202464

How it is read

Names in the registry

  • “Pumitamig”, 18 entries
  • “PM8002”, 11 entries
  • “BNT327”, 3 entries
  • “BNT327 Dose Level 1 (DL1)”, 2 entries
  • “BNT327 Dose Level 2 (DL2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.